Featured tickers: $ARWR $BLUE $BMY $DRTX $GILD $KITE $PFE $SNSS $SRPT $ZIOP $IBB $XBI
What's missing from brouhaha over drug pricing? Congress chose NOT to give the CMS negotiating power on prices. $PFE Kindler's last hurrah
— Sally Church (@MaverickNY) October 6, 2014 Happy for the Nobel prize to the Mosers for many reasons.I love to see Systems Neuroscience recognized and also great and serious careers!
— Alfredo Fontanini (@AF_biotech) October 6, 2014 In Boston alone there are 8,000 postdocs. On Earth there are 7,000 rare diseases. Pair a postdoc with a #raredisease -> biomed moonshot.
— Ethan O. Perlstein (@eperlste) October 6, 2014 $SNSS given my rule #FailureisTheRuleNotTheException, tried all last week getting puts ahead of likely bad data, did.not.get.single.contract
— WiseRguy (@wiseRguy1971) October 6, 2014 Jonathan Lewis of $ZIOP: Some of the issues w/ CAR T systemwide immunity, acute toxicity, may be fixed by slowing infusion rates #BIF14
— Luke Timmerman (@ldtimmerman) October 7, 2014 oh my gosh, @GoldmanSachs is down what? 50% since their neutral call on $GILD, best advice in biotech is dont listen to Goldman Sachs
— Dr. Paul DeSantis (@DrPaulyDeSantis) October 7, 2014 Open RSS Reader. Find all: "Ebola." Mark as: "Read."
— Alexander Gaffney (@AlecGaffney) October 7, 2014 Wow, $BMY pulling their FDA application for hep C combo, citing "rapidly evolving hep C treatment landscape."
— Drew Armstrong (@ArmstrongDrew) October 7, 2014 Seriously though, so many CEOs are hesitant to use social media, but this shows how easy it is to be compliant. Send one PR and you are okay
— Brad Loncar (@bradloncar) October 8, 2014 If u trade bios freq, at some point there'll be a day like $DRTX holders had past Mon & a day like $ARWR holders today. Nature of the beast.
— 23aloha (@23aloha) October 8, 2014 Made the wrong call on $ARWR. Dissapointed in myself for not heeding to the numerous red flags pic.twitter.com/5Al22ALy50
— Zack (@BioTerp) October 8, 2014 Cowen saying feedback from their conference is that both $KITE and $BLUE have the most disruptive technologies in their respective spaces
— Ian Estepan (@ianestepan) October 8, 2014 sold all of my $ARWR. will re-enter later once they get their 1log dose. There is science and there is trading. Keep me is check Tweeps
— avidresearch (@avidresearch) October 8, 2014 But the baker brothers own it.....
— NathanAaron (@NathanAhron) October 8, 2014 biotech is so much easier w/o the actual data
— zach (@zbiotech) October 8, 2014 $ARWR - That's why you should have never released blinded data. Very unprofessional and very risky...
— Andy Biotech (@AndyBiotech) October 8, 2014 MT @adamfeuerstein Science is not investing & vice versa. Different disciplines, knowledge base, experience, skill set.
— David Miller (@AlpineBV_Miller) October 8, 2014 Is the early trading day selling automatic program done yet !!! $SPY $IWM $IBB $XBI
— Joe (@GantosJ) October 9, 2014 arent these days how you make money in the stock market?
— happycamper (@happyycamperr) October 9, 2014 Turned on CNBC for the first time in a while. Wow...these guys sound nervous. Turning off, back to my spreadsheet.
— Emory Redd (@Emory_R) October 9, 2014 .@DavidJuurlink But the best researchers? They say what they think, & remain in demand. Companies that can't take criticism screw up.
— Matthew Herper (@matthewherper) October 10, 2014 So now we play the weekly script watching game (again). $GILD
— David Sobek (@dsobek) October 10, 2014 Bought $SRPT at the close, same amount as Sept buy because when a week like this doesn't give you enough anxiety I like to ruin my weekend.
— John Hall (@johnhallnj) October 10, 2014 I have a separate to-do list on my phone for all the pts I have to order harvoni for next week.
— biotechnicality (@biotechnicality) October 10, 2014 
RSS Feed
